MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (MLTX) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for MoonLake Immunotherapeutics (MLTX), covering cash flow, earnings, and balance sheets.
MoonLake Immunotherapeutics (MLTX) Income Statement & Financial Overview
Access detailed annual and quarterly income data for MoonLake Immunotherapeutics MLTX financial performance.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $101850.00 | $0.00 |
| Cost of Revenue | $0.00 | $378000.00 | $50925.00 | $32515.00 |
| Gross Profit | $0.00 | -$378000.00 | $50925.00 | -$32515.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.50 | $0.00 |
| R&D Expenses | $49.76M | $36.46M | $40.36M | $35.74M |
| SG&A Expenses | $10.94M | $11.03M | $9.22M | $7.38M |
| Operating Expenses | $60.70M | $47.48M | $49.58M | $43.11M |
| Total Costs & Expenses | $0.00 | $47.48M | -$49.58M | $43.11M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | -$2.04M | -$18000.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $378000.00 | $1.30M | $32515.00 |
| EBITDA | $0.00 | -$40.01M | -$45.05M | -$43.08M |
| EBITDA Ratio | $0.00 | $0.00 | -$442.35 | $0.00 |
| Operating Income | $0.00 | -$47.48M | -$49.58M | -$43.11M |
| Operating Income Ratio | $0.00 | $0.00 | -$486.80 | $0.00 |
| Other Income/Expenses (Net) | $0.00 | $7.08M | $3.23M | $7.09M |
| Income Before Tax | -$55.96M | -$40.41M | -$46.35M | -$36.02M |
| Income Before Tax Ratio | $0.00 | $0.00 | -$455.13 | $0.00 |
| Income Tax Expense | -$95000.00 | -$153000.00 | $41140.00 | $92106.00 |
| Net Income | -$55.86M | -$40.25M | -$45.60M | -$35.39M |
| Net Income Ratio | $0.00 | $0.00 | -$447.76 | $0.00 |
| EPS | -$0.87 | -$0.63 | -$0.72 | -$0.56 |
| Diluted EPS | -$0.87 | -$0.63 | -$0.72 | -$0.56 |
| Weighted Avg Shares Outstanding | $63.28M | $63.23M | $63.07M | $62.90M |
| Weighted Avg Shares Outstanding (Diluted) | $63.28M | $63.23M | $63.07M | $62.90M |
Financial performance has remained strong, with revenue growing from $0.00 in Q3 2024 to $0.00 in Q2 2025. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached $0.00 in Q2 2025, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $0.00. Net income dropped to -$55.86M, keeping EPS at -$0.87. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan